-
Tytuł:
-
Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study.
-
Autorzy:
-
Shepherd L; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom.
Ryom L; Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section, Rigshospitalet, University of Copenhagen, Denmark.
Law M; Kirby Institute, University of New South Wales, Sydney, Australia.
Petoumenos K; Kirby Institute, University of New South Wales, Sydney, Australia.
Hatleberg CI; Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section, Rigshospitalet, University of Copenhagen, Denmark.
d'Arminio Monforte A; Dipartimento di Scienze della Salute, Clinica di Malattie Infettive e Tropicali, Azienda Ospedaliera-Polo Universitario San Paolo, Milan, Italy.
Sabin C; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom.
Bower M; National Centre for HIV Malignancy, Chelsea and Westminster Hospital, London, United Kingdom.
Bonnet F; Centre Hospitalier Universitaire de Bordeaux and Institut National de la Santé et de la Recherche Médicale, Université de Bordeaux, France.
Reiss P; Academic Medical Center, Department of Global Health and Division of Infectious Diseases, University of Amsterdam.; HIV Monitoring Foundation, Amsterdam, The Netherlands.
de Wit S; Division of Infectious Diseases, Saint Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Pradier C; Department of Public Health, Nice University Hospital, France.
Weber R; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Switzerland.
El-Sadr W; ICAP-Columbia University and Harlem Hospital, New York, New York.
Lundgren J; Centre of Excellence for Health, Immunity and Infections, Department of Infectious Diseases, Section, Rigshospitalet, University of Copenhagen, Denmark.
Mocroft A; Centre for Clinical Research, Epidemiology, Modelling and Evaluation, Institute for Global Health, University College London, United Kingdom.
-
Corporate Authors:
-
Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group
-
Źródło:
-
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2019 Feb 01; Vol. 68 (4), pp. 650-657.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Jan. 2011- : Oxford : Oxford University Press
Original Publication: Chicago, IL : The University of Chicago Press, c1992-
-
MeSH Terms:
-
HIV Infections/*complications
Neoplasms/*epidemiology
Neoplasms/*prevention & control
Smoking Cessation/*statistics & numerical data
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prospective Studies
-
Entry Date(s):
-
Date Created: 20180619 Date Completed: 20200317 Latest Revision: 20200317
-
Update Code:
-
20240105
-
DOI:
-
10.1093/cid/ciy508
-
PMID:
-
29912335
-
Background: Cancers are a major source of morbidity and mortality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown.
Methods: Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex-smoker, current smoker, and never smoker. Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for demographic and clinical factors.
Results: In total 35442 persons from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-years of follow-up. At baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked. Incidence of all cancers combined (n = 2183) was highest <1 year after smoking cessation compared to never smokers (aIRR, 1.66 [95% confidence interval {CI}, 1.37-2.02]) and not significantly different from never smokers 1-1.9 years after cessation. Lung cancer incidence (n = 271) was elevated <1 year after cessation (aIRR, 19.08 [95% CI, 8.10-44.95]) and remained 8-fold higher 5 years after smoking cessation (aIRR, 8.69 [95% CI, 3.40-22.18]). Incidence of other smoking-related cancers (n = 622) was elevated in the first year after cessation (aIRR, 2.06 [95% CI, 1.42-2.99]) and declined to a level similar to nonsmokers thereafter.
Conclusions: Lung cancer incidence in HIV-infected individuals remained elevated >5 years after smoking cessation. Deterring uptake of smoking and smoking cessation efforts should be prioritised to reduce future cancer risk.